Inhibikase terminates unused ATM facility; no impact on capital

Inhibikase Therapeutics, Inc.

Terminated ATM agreement with H.C. Wainwright effective Dec 11, 2024.
Original ATM limit was $5.66M; only $849k sold before reduction to $50k.
No shares sold under ATM since May 20, 2024.
Termination ends ability to issue equity at market via this facility.

item 1.02

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-271609

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.